Clover Health Investments (CLOV) Investor presentation summary

Investment highlights and business model

• AI-driven platform enables physician-led care and supports improved clinical outcomes, scaling with commercial LLM innovation.

• Achieved 53% AEP growth, over 95% retention, and stable year-over-year benefits.

• National leader in Medicare Advantage PPO quality, with a #1 HEDIS score of 4.72 for 2026.

• Differentiated, tech-centric model focuses on early disease identification and management, wide network PPO, and affordability.

• AI/ML models generate millions of personalized clinical insights, supporting thousands of practitioners.

Financial performance and guidance

• FY25 Adjusted EBITDA profitability achieved with 38% membership and 40% revenue growth year-over-year.

• FY26 guidance projects 46% membership growth, 49% revenue growth, and $50M–$70M Adjusted EBITDA.

• Expectation to deliver FY26 GAAP Net Income profitability, a $96M improvement from FY25.

• Cohort economics improving, with strong retention and increasing Clover Assistant coverage driving future margin expansion.

• Layered cohort profitability and growing membership create compounding profitability over time.

Clinical outcomes and technology impact

• Clover Assistant use leads to earlier diagnosis and treatment of chronic diseases, fewer hospitalizations, and improved medication adherence.

• Demonstrated 18% lower CHF hospitalizations, 15% lower COPD hospitalizations, and significant improvements in diabetes and CKD management.

• Higher diagnosis rates and earlier detection for socioeconomically disadvantaged populations, with 8–21% fewer hospitalizations.

• Medication adherence improved by 3–5% post-visit for previously non-adherent patients.

• Consistently top-rated PPO plan on HEDIS measures for two consecutive years.